Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.08%
#4 aPriori aPriori +187.76%
#5 Bedrock Bedrock +78.72%
#6 Cysic Cysic +52.73%
#7 Prom Prom +43.01%
#8 Playnance Playnance +34.94%
#9 Bitway Bitway +27.98%
#10 COTI COTI +25.34%
Coin of the day
Wrapped One Wrapped One
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Poniard Pharmaceuticals, Inc. Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
Classement en actions #42764
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Prix de l'action
$0.0001
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$150.00
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Poniard Pharmaceuticals, Inc. (PARD)

Catégorie

Healthcare
Bénéfices pour Poniard Pharmaceuticals, Inc. (PARD)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Poniard Pharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Poniard Pharmaceuticals, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR